GLPwatch
Papers (10404)
Page 73 of 174, ranked by citation count.
- Glucagon-like peptide-1 gene therapy.
- Glucagon-like peptide-1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity-a systematic review and network meta-analysis.
- Tirzepatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist, exhibits favourable effects on pancreatic β-cells and hepatic steatosis in obese type 2 diabetic db/db mice.
- Semaglutide: a new drug for the treatment of obesity.
- Liraglutide improves obesity-induced renal injury by alleviating uncoupling of the glomerular VEGF-NO axis in obese mice.
- A post hoc analysis of long-term prognosis after exenatide treatment in patients with ST-segment elevation myocardial infarction.
- Combined use of immunoassay and two-dimensional liquid chromatography mass spectrometry for the detection and identification of metabolites from biotherapeutic pharmacokinetic samples.
- C-terminal site-specific PEGylated Exendin-4 analog: A long-acting glucagon like Peptide-1 receptor agonist, on glycemic control and beta cell function in diabetic db/db mice.
- Diastolic Cardiac Function Improvement by Liraglutide Is Mainly Body Weight Reduction Dependent but Independently Contributes to B-Type Natriuretic Peptide Reduction in Patients with Type 2 Diabetes with Preserved Ejection Fraction.
- Targeting Persistent Neuroinflammation after Hypoxic-Ischemic Encephalopathy-Is Exendin-4 the Answer?
- Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
- Enhanced Gut-to-Liver Oral Drug Delivery via Ligand-Modified Nanoparticles by Attenuating Protein Corona Adsorption.
- Liraglutide Attenuates Glucolipotoxicity-Induced RSC96 Schwann Cells' Inflammation and Dysfunction.
- Long-Acting Phospholipid Gel of Exenatide for Long-Term Therapy of Type II Diabetes.
- Lack of effect of prolonged treatment with liraglutide on cardiac remodeling in rats after acute myocardial infarction.
- Effectiveness and safety of a GLP-1 agonist in obese patients with inflammatory bowel disease.
- Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study.
- Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Suboptimal Initial Clinical Response and Weight Gain Recurrence After Bariatric Surgery: a Systematic Review and Meta-analysis.
- Adverse drug reaction patterns of GLP-1 receptor agonists approved for obesity treatment: Disproportionality analysis from global pharmacovigilance database.
- Metabolic measures 12 months after a randomised controlled trial of treatment of clozapine associated obesity and diabetes with exenatide (CODEX).
- Pharmacological and non-pharmacological strategies for obese women with subfertility.
- Role of Renal Sympathetic Nerves in GLP-1 (Glucagon-Like Peptide-1) Receptor Agonist Exendin-4-Mediated Diuresis and Natriuresis in Diet-Induced Obese Rats.
- Efficacy and safety of oral semaglutide in type 2 diabetes: A systematic review of real-world evidence.
- The Effect of Tirzepatide on Body Composition in People with Overweight and Obesity: A Systematic Review of Randomized, Controlled Studies.
- GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician?
- Allocation of Semaglutide According to Coronary Artery Calcium and BMI: Applying the SELECT Trial to MESA.
- Impact of the Glucagon Assay When Assessing the Effect of Chronic Liraglutide Therapy on Glucagon Secretion.
- Real-world safety profile of once-weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real-world Evidence (SURE) programme.
- Chitosan based surface modulation of core-shell nanoparticles for oral delivery of exenatide via balancing mucus penetration and cellular uptake.
- Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.
- Cardiovascular side-effects and insulin secretion after intravenous administration of radiolabeled Exendin-4 in pigs.
- Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes.
- Exenatide Once Weekly: A Review of Pharmacology and Treatment Considerations in Type 2 Diabetes.
- Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update.
- Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects.
- Differential hypoglycaemic, anorectic, autonomic and emetic effects of the glucagon-like peptide receptor agonist, exendin-4, in the conscious telemetered ferret.
- Pharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases.
- IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy.
- Using RWE research to extend clinical trials in diabetes: An example with implications for the future.
- Hypoglycemic drug liraglutide alleviates low muscle mass by inhibiting the expression of MuRF1 and MAFbx in diabetic muscle atrophy.
- Glucagon-Like Peptide-1 Agonists: A Practical Overview for Plastic and Reconstructive Surgeons.
- GLP-1 receptor agonist, liraglutide, protects podocytes from apoptosis in diabetic nephropathy by promoting white fat browning.
- Engineering a novel protease-based Exendin-4 derivative for type 2 antidiabetic therapeutics.
- Dietary Calanus oil recovers metabolic flexibility and rescues postischemic cardiac function in obese female mice.
- Achievement of normoglycemia with tirzepatide in type 2 diabetes mellitus: A step closer to drug-induced diabetes remission?
- Toward a Medical Gastric Bypass: Chronic Feeding Studies With Liraglutide + PYY<sub>3-36</sub> Combination Therapy in Diet-Induced Obese Rats.
- A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetes.
- In vitro metabolic stability of exendin-4: pharmacokinetics and identification of cleavage products.
- Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2).
- EFFICACY AND SAFETY OF DULAGLUTIDE IN HISPANIC/LATINO PATIENTS WITH TYPE 2 DIABETES IN THE AWARD CLINICAL PROGRAM.
- Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors.
- Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes.
- Liraglutide Improves PCOS Symptoms in Rats by Targeting FDX1.
- GLP-1 receptor agonists in type 1 diabetes: a MAG1C bullet?
- Exendin-4, a glucagon-like peptide-1 receptor agonist, suppresses pancreatic β-cell destruction induced by encephalomyocarditis virus.
- Mapping in vivo microclimate pH distribution in exenatide-encapsulated PLGA microspheres.
- Liraglutide Treatment Ameliorates Neurotoxicity Induced by Stable Silencing of Pin1.
- Albiglutide: Is a better hope against diabetes mellitus?
- Liraglutide and the management of overweight and obesity in people with severe mental illness: qualitative sub-study.
- IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes.